Government ContextGovernment Context
ActivityRulesGrantsPress releasesHearingsBills
ViewsAgenciesTopicsOrganizationsCommitteesLegislators
PricingLog inCreate account
Details

Opioid Analgesic Drugs: Considerations for Benefit-Risk Assessment Framework Guidance for Industry; Draft Guidance

FDA-2019-D-1536-0037Other
Document

Details

The document's own metadata, straight from the source system.

Title
Opioid Analgesic Drugs: Considerations for Benefit-Risk Assessment Framework Guidance for Industry; Draft Guidance
Posted
May 13, 2026
Agency
Food and Drug Administration (FDA)
View on regulations.gov ↗